首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
【24h】

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

机译:TET2改变在急性髓样白血病从新获得完全缓解的发生率和预后价值。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Mutations of the ten eleven translocation 2 gene (TET2) have recently been reported in myelodysplastic syndrome and myeloproliferative neoplasms. We analyzed the incidence and prognostic value of TET2 point mutations and other genomic alterations by direct sequencing and single nucleotide polymorphism microarray analysis in 111 de novo acute myeloid leukemia, who had all achieved complete remission (CR). Mutations were observed in 19 (17%) of the 111 patients compared with 10 (27%) of 36 patients who had failed to achieve CR (P = .2). In the 111 patients who had achieved CR, TET2 alterations were only significantly associated with NPM1 mutations but not with other pretreatment characteristics. TET2 gene status was not significantly correlated with disease-free survival and overall survival, both in the entire cohort and in patients with normal karyotype.
机译:最近在骨髓增生异常综合症和骨髓增生性肿瘤中报道了十一个11易位2基因(TET2)的突变。我们通过直接测序和单核苷酸多态性微阵列分析对111例已经完全缓解(CR)的急性髓性白血病的TET2点突变和其他基因组改变的发生率和预后价值进行了分析。 111例患者中有19例(17%)发生突变,而36例未达到CR的患者中有10例(27%)(P = .2)。在111位获得CR的患者中,TET2改变仅与NPM1突变显着相关,而与其他预处理特征无显着相关性。在整个队列和正常核型患者中,TET2基因状态与无病生存期和总生存期均无显着相关性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号